| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| 3 | Initial filing by director officer or owner of more than ten percent |
3,4,5
|
||
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
||
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
||
| 144 | Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing |
Other
|
||
| SC 13G/A | An amendment to the SC 13G filing |
Other
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| SC 13D/A | An amendment to a SC 13D filing |
Other
|
||
| 8-K/A | Amendment to a previously filed 8-K |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| 8-K/A | Amendment to a previously filed 8-K |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA |
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.
